How do you pay?

How to pay the least

Ask for the cash price

Pegasys

Pegasys is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

  1. Ask your pharmacy for Pegasys’s cash price, and one or two other pharmacies too.

Compare every option

Question
Brand namePegasys
Authorized genericpeginterferon alfa-2a
Regular genericpeginterferon alfa-2a
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Pegasys?
The original
–
–

Brand nameNo maker’s card

We didn’t find a savings card or cash price from Pegasys’s maker. Ask the pharmacy for Pegasys’s cash price. With insurance, ask what your plan charges.

Authorized genericNot sold

There isn’t one. An authorized generic is Pegasys itself, from the same company, sold without the brand name, and usually for less. For now Pegasys is the only choice; ask the pharmacy for its cash price, or your plan what it charges.

Regular genericNot sold

Pegasys is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, ask the pharmacy for Pegasys’s cash price, or your plan what it charges.

What it’s used for

What the FDA label says

PEGASYS is an inducer of the innate immune response indicated for the treatment of

Chronic Hepatitis C (CHC)

  • Adult Patients: In combination therapy with other hepatitis C virus drugs for adults with compensated liver disease. PEGASYS monotherapy is indicated only if patient has contraindication or significant intolerance to other HCV drugs.
  • Pediatric Patients: In combination with ribavirin for pediatric patients 5 years of age and older with compensated liver disease

Chronic Hepatitis B (CHB)

  • Adult Patients: Treatment of adults with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) infection who have compensated liver disease and evidence of viral replication and liver inflammation
  • Pediatric Patients: Treatment of non-cirrhotic pediatric patients 3 years of age and older with HBeAg-positive CHB and evidence of viral replication and elevations in serum alanine aminotransferase (ALT)

Source: the FDA label for Pegasys (pharmaand GmbH), September 2, 2026. Full label on DailyMed 

Good to know